The US Food and Drug Administration is exploring whether regulatory changes are needed to advance modern clinical trial designs as part of the Center for Drug Evaluation and Research’s newly launched Center for Clinical Trial Innovation (C3TI) initiative.
US FDA Looking To Modernize Clinical Trial Regulations To Spur ‘Evolution’ In Research
The Center for Drug Evaluation and Research’s new Center for Clinical Trial Innovation (C3TI) may lead a “targeted” effort to update the FDA’s regulatory framework given advances in trial design and execution, CDER Director Patrizia Cavazzoni said. Industry already has asks.
